ALX Oncology Holdings Receives Hold Rating from LifeSci Capital

ALX Oncology Holdings (ALXO) received a Hold rating from LifeSci Capital analyst Sam Slutsky. The company's shares closed at $0.66. ALXO has an analyst consensus of Strong Buy with a price target consensus of $2.00. The company has a one-year high of $2.73 and a one-year low of $0.40. ALXO has an average volume of 526.3K.

ALX Oncology Holdings Inc. (NASDAQ: ALXO) has extended its cash runway guidance to the first quarter of 2027, providing financial stability as it pursues its clinical pipeline. The company reported promising results from the ASPEN-06 trial, with a 65% overall response rate (ORR) in CD47-high and HER2-positive patients, compared to 26% in the control group. The duration of response (DOR) in the experimental arm was 15.7 months versus 9.1 months in the control arm [1].

ALX Oncology has also modified its Phase 2 clinical trial in breast cancer to focus on a CD47 and HER2 biomarker-driven strategy, which could enhance targeted oncology approaches. The company is on track to dose its first patient with its novel EGFR-targeted ADC, ALX2004, this month, indicating progress in its clinical pipeline [1].

The company's partnership with Sanofi in a randomized Phase 1/2 study has completed its initial phase, and Sanofi will now begin the dose optimization portion, demonstrating collaborative progress. However, the ASPEN-06 trial results require further validation and presentation at an upcoming medical conference, indicating that more data is needed for conclusive results [1].

ALX Oncology's shares closed at $0.66 on July 2, 2025, with an analyst consensus of Strong Buy and a price target consensus of $2.00. The company has a one-year high of $2.73 and a one-year low of $0.40, with an average volume of 526.3K shares traded daily [2].

References:
[1] https://sg.finance.yahoo.com/news/alx-oncology-holdings-inc-alxo-071344371.html
[2] https://sg.finance.yahoo.com/news/alx-oncology-holdings-inc-alxo-071344371.html